UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2017
or
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-33301
ACCURAY INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware |
|
20-8370041 |
|
(State or Other Jurisdiction of Incorporation or Organization) |
|
(IRS Employer Identification Number) |
1310 Chesapeake Terrace
Sunnyvale, California 94089
(Address of Principal Executive Offices Including Zip Code)
(408) 716-4600
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes o No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
|
Large accelerated filer o |
|
Accelerated filer x |
|
|
|
|
|
Non-accelerated filer o |
|
Smaller reporting company o |
|
(Do not check if a smaller reporting company) |
|
|
|
|
|
Emerging growth company o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes x No
As of January 25, 2018, there were 85,293,273 shares of the Registrant’s Common Stock, par value $0.001 per share, outstanding.
We own or have rights to various trademarks and trade names used in our business in the United States or other countries, including the following: Accuray®, Accuray Logo®, CyberKnife®, Hi-Art®, RoboCouch®, Synchrony®, TomoTherapy®, Xsight®, Accuray Precision™, AutoSegmentation™, CTrue™, H™ Series, iDMS™, InCise™, Iris™, M6™ Series, OIS Connect™, PlanTouch™, PreciseART™, PreciseRTX™, QuickPlan™, TomoDirect™, TomoEdge™, TomoH™, TomoHD™, TomoHDA™, TomoHelical™, Tomo Quality Assurance™, Radixact™, StatRT™, and VoLO™.
Item 1. Unaudited Condensed Consolidated Financial Statements
Accuray Incorporated
Unaudited Condensed Consolidated Balance Sheets
(in thousands, except share amounts and par value)
|
|
|
December 31, |
|
June 30, |
| ||
|
|
|
2017 |
|
2017 |
| ||
|
ASSETS |
|
|
|
|
| ||
|
Current assets: |
|
|
|
|
| ||
|
Cash and cash equivalents |
|
$ |
79,509 |
|
$ |
72,084 |
|
|
Short-term investments |
|
24,516 |
|
23,909 |
| ||
|
Restricted cash |
|
2,039 |
|
12,829 |
| ||
|
Accounts receivable, net of allowance for doubtful accounts of $442 and $420 as of December 31, 2017 and June 30, 2017, respectively |
|
80,907 |
|
72,789 |
| ||
|
Inventories |
|
113,809 |
|
105,054 |
| ||
|
Prepaid expenses and other current assets |
|
15,577 |
|
18,988 |
| ||
|
Deferred cost of revenue |
|
2,316 |
|
3,350 |
| ||
|
Total current assets |
|
318,673 |
|
309,003 |
| ||
|
Property and equipment, net |
|
22,601 |
|
23,062 |
| ||
|
Goodwill |
|
57,910 |
|
57,812 |
| ||
|
Intangible assets, net |
|
893 |
|
964 |
| ||
|
Restricted cash |
|
629 |
|
322 |
| ||
|
Other assets |
|
13,231 |
|
15,301 |
| ||
|
Total assets |
|
$ |
413,937 |
|
$ |
406,464 |
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
| ||
|
Current liabilities: |
|
|
|
|
| ||
|
Accounts payable |
|
$ |
25,922 |
|
$ |
17,486 |
|
|
Accrued compensation |
|
22,231 |
|
25,402 |
| ||
|
Other accrued liabilities |
|
19,514 |
|
23,870 |
| ||
|
Short-term debt |
|
39,451 |
|
113,023 |
| ||
|
Customer advances |
|
19,797 |
|
16,926 |
| ||
|
Deferred revenue |
|
79,955 |
|
87,785 |
| ||
|
Total current liabilities |
|
206,870 |
|
284,492 |
| ||
|
Long-term liabilities: |
|
|
|
|
| ||
|
Long-term other liabilities |
|
10,794 |
|
10,068 |
| ||
|
Deferred revenue |
|
16,737 |
|
13,823 |
| ||
|
Long-term debt |
|
130,425 |
|
51,548 |
| ||
|
Total liabilities |
|
364,826 |
|
359,931 |
| ||
|
Commitments and contingencies (Note 8) |
|
|
|
|
| ||
|
Stockholders’ equity: |
|
|
|
|
| ||
|
Common stock, $0.001 par value; authorized: 200,000,000 shares as of December 31, 2017 and June 30, 2017, respectively; issued and outstanding: 85,287,635 and 83,739,804 shares at December 31, 2017 and June 30, 2017, respectively |
|
85 |
|
84 |
| ||
|
Additional paid-in-capital |
|
512,883 |
|
496,887 |
| ||
|
Accumulated other comprehensive income (loss) |
|
630 |
|
(52 |
) | ||
|
Accumulated deficit |
|
(464,487 |
) |
(450,386 |
) | ||
|
Total stockholders’ equity |
|
49,111 |
|
46,533 |
| ||
|
Total liabilities and stockholders’ equity |
|
$ |
413,937 |
|
$ |
406,464 |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Accuray Incorporated
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
|
December 31, |
|
December 31, |
| ||||||||
|
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
| ||||
|
Net revenue: |
|
|
|
|
|
|
|
|
| ||||
|
Products |
|
$ |
47,106 |
|
$ |
35,398 |
|
$ |
86,022 |
|
$ |
70,997 |
|
|
Services |
|
53,223 |
|
52,104 |
|
105,257 |
|
103,011 |
| ||||
|
Total net revenue |
|
100,329 |
|
87,502 |
|
191,279 |
|
174,008 |
| ||||
|
Cost of revenue: |
|
|
|
|
|
|
|
|
| ||||
|
Cost of products |
|
26,857 |
|
22,969 |
|
48,959 |
|
46,321 |
| ||||
|
Cost of services |
|
34,117 |
|
33,146 |
|
64,859 |
|
64,956 |
| ||||
|
Total cost of revenue |
|
60,974 |
|
56,115 |
|
113,818 |
|
111,277 |
| ||||
|
Gross profit |
|
39,355 |
|
31,387 |
|
77,461 |
|
62,731 |
| ||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
| ||||
|
Research and development |
|
14,664 |
|
11,944 |
|
28,757 |
|
24,173 |
| ||||
|
Selling and marketing |
|
13,872 |
|
13,904 |
|
28,629 |
|
28,222 |
| ||||
|
General and administrative |
|
11,836 |
|
10,362 |
|
23,144 |
|
21,706 |
| ||||
|
Total operating expenses |
|
40,372 |
|
36,210 |
|
80,530 |
|
74,101 |
| ||||
|
Loss from operations |
|
(1,017 |
) |
(4,823 |
) |
(3,069 |
) |
(11,370 |
) | ||||
|
Other expense, net |
|
(3,738 |
) |
(4,120 |
) |
(10,309 |
) |
(8,125 |
) | ||||
|
Loss before provision for income taxes |
|
(4,755 |
) |
(8,943 |
) |
(13,378 |
) |
(19,495 |
) | ||||
|
Provision for (benefit from) income taxes |
|
(36 |
) |
426 |
|
723 |
|
(200 |
) | ||||
|
Net loss |
|
$ |
(4,719 |
) |
$ |
(9,369 |
) |
$ |
(14,101 |
) |
$ |
(19,295 |
) |
|
|
|
|
|
|
|
|
|
|
| ||||
|
Net loss per share - basic and diluted |
|
$ |
(0.06 |
) |
$ |
(0.11 |
) |
$ |
(0.17 |
) |
$ |
(0.24 |
) |
|
Weighted average common shares used in computing net loss per share: |
|
|
|
|
|
|
|
|
| ||||
|
Basic and diluted |
|
84,586 |
|
82,328 |
|
84,167 |
|
81,952 |
| ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
Net loss |
|
$ |
(4,719 |
) |
$ |
(9,369 |
) |
$ |
(14,101 |
) |
$ |
(19,295 |
) |
|
Foreign currency translation adjustment |
|
212 |
|
(1,325 |
) |
558 |
|
(1,206 |
) | ||||
|
Unrealized gain (loss) on investments, net of tax |
|
102 |
|
(68 |
) |
124 |
|
(70 |
) | ||||
|
Comprehensive loss |
|
$ |
(4,405 |
) |
$ |
(10,762 |
) |
$ |
(13,419 |
) |
$ |
(20,571 |
) |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Accuray Incorporated
Unaudited Condensed Consolidated Statements of Cash Flows
(in thousands)
|
|
|
Six Months Ended |
| ||||
|
|
|
December 31, |
| ||||
|
|
|
2017 |
|
2016 |
| ||
|
Cash flows from operating activities |
|
|
|
|
| ||
|
Net loss |
|
$ |
(14,101 |
) |
$ |
(19,295 |
) |
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
| ||
|
Depreciation and amortization |
|
5,007 |
|
9,280 |
| ||
|
Share-based compensation |
|
5,870 |
|
6,387 |
| ||
|
Amortization of debt issuance costs |
|
868 |
|
782 |
| ||
|
Amortization and accretion of discount and premium on investments |
|
(10 |
) |
63 |
| ||
|
Accretion of interest on debt |
|
1,727 |
|
1,456 |
| ||
|
Provision for (recovery of) bad debt, net |
|
22 |
|
(63 |
) | ||
|
Provision for write-down of inventories |
|
1,189 |
|
665 |
| ||
|
Loss on disposal of property and equipment |
|
11 |
|
— |
| ||
|
Loss on extinguishment of debt |
|
3,192 |
|
— |
| ||
|
Changes in assets and liabilities: |
|
|
|
|
| ||
|
Accounts receivable |
|
(10,156 |
) |
(14,248 |
) | ||
|
Inventories |
|
(11,832 |
) |
(2,559 |
) | ||
|
Prepaid expenses and other assets |
|
5,855 |
|
(231 |
) | ||
|
Deferred cost of revenue |
|
1,206 |
|
1,471 |
| ||
|
Accounts payable |
|
8,085 |
|
10,070 |
| ||
|
Accrued liabilities |
|
(8,059 |
) |
(2,602 |
) | ||
|
Customer advances |
|
2,787 |
|
3,119 |
| ||
|
Deferred revenues |
|
(5,401 |
) |
(5,317 |
) | ||
|
Net cash used in operating activities |
|
(13,740 |
) |
(11,022 |
) | ||
|
Cash flows from investing activities |
|
|
|
|
| ||
|
Purchases of property and equipment, net |
|
(1,977 |
) |
(3,136 |
) | ||
|
Purchases of investments |
|
(5,940 |
) |
(14,992 |
) | ||
|
Sales and maturities of investments |
|
6,000 |
|
23,190 |
| ||
|
Net cash (used in) provided by investing activities |
|
(1,917 |
) |
5,062 |
| ||
|
Cash flows from financing activities |
|
|
|
|
| ||
|
Proceeds from employee stock plans |
|
2,036 |
|
2,050 |
| ||
|
Taxes paid related to net share settlement of equity awards |
|
(293 |
) |
(737 |
) | ||
|
Proceeds from issuance of Term Loan, net |
|
38,829 |
|
— |
| ||
|
Proceeds from issuance of Convertible Notes, net |
|
27,282 |
|
— |
| ||
|
Repurchase of Convertible Notes |
|
(29,581 |
) |
(42,483 |
) | ||
|
Borrowings under revolving credit facility |
|
68,171 |
|
— |
| ||
|
Repayments under revolving credit facility |
|
(94,736 |
) |
— |
| ||
|
Net cash provided by (used in) financing activities |
|
11,708 |
|
(41,170 |
) | ||
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
891 |
|
(3,646 |
) | ||
|
Net decrease in cash, cash equivalents and restricted cash |
|
(3,058 |
) |
(50,776 |
) | ||
|
Cash, cash equivalents and restricted cash at beginning of period |
|
85,235 |
|
122,133 |
| ||
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
82,177 |
|
$ |
71,357 |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Accuray Incorporated
Notes to Unaudited Condensed Consolidated Financial Statements
Description of Business
Accuray Incorporated (together with its subsidiaries, the “Company” or “Accuray”) designs, develops and sells advanced radiosurgery and radiation therapy systems for the treatment of tumors throughout the body. The Company is incorporated in Delaware and has its principal place of business in Sunnyvale, California. The Company has primary offices in the United States, Switzerland, China, Hong Kong and Japan and conducts its business worldwide.
Note 1. Basis of Presentation and Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation.
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and note disclosures have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the periods presented. Certain amounts in the prior year’s condensed consolidated balance sheet have been reclassified to conform to the current period’s presentation. The results for the three and six months ended December 31, 2017 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2018, or for any other future interim period or fiscal year.
These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes for the fiscal year ended June 30, 2017 included in the Company’s Annual Report on Form 10-K filed with the SEC on August 25, 2017. The Company’s significant accounting policies are described in Note 2 to those audited consolidated financial statements and there have been no subsequent material changes to such policies.
Note 2. Recent Accounting Pronouncements
Accounting Pronouncement Recently Adopted
In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718). The new guidance simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. In addition, the guidance provides an option to recognize forfeitures as they occur versus estimating them at the time of grant. The amendments in this standard are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted ASU No. 2016-09 as required in the first quarter of fiscal year 2018 and has elected to continue the use of its forfeiture estimation method for share-based payment awards. The adoption of ASU 2016-09 did not have a material impact on the Company’s consolidated financial statements and related disclosures.
Accounting Pronouncements Not Yet Effective
In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718)—Scope of Modification Accounting. This guidance redefines which changes to the terms and conditions of a share-based payment award require an entity to apply modification accounting for a share-based payment. This guidance will be effective for the Company in the first quarter of its fiscal year 2019. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.
In March 2017, the FASB issued ASU No. 2017-07, Compensation—Retirement Benefits (Topic 715)—Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This guidance revises the presentation of employer-sponsored defined benefit pension and other postretirement plans for the net periodic benefit cost in the statement of operations and requires that the service cost component of net periodic benefit be presented in the same income statement line items as other employee compensation costs for services rendered during the period. The other components of the net benefit costs are required to be presented in the statement of operations separately from the service cost component and outside the subtotal of income from
operations. This guidance allows only the service cost component of net periodic benefit costs to be eligible for capitalization. The guidance will be effective for the Company in the first quarter of its fiscal year 2019. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements and related disclosures.
In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other Topics (Topic 350)-Simplifying the Test for Goodwill Impairment. This guidance simplifies the measurement of goodwill by eliminating the Step 2 impairment test. The new guidance requires companies to perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. This ASU will be effective for the Company beginning in its first quarter of fiscal year 2021. The amendment is required to be adopted prospectively. Early adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which clarifies the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. This ASU will be effective for the Company in the first quarter of its fiscal year 2019. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.
In June 2016, the FASB issued ASU No. 2016-13 Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets held. This ASU will be effective for the Company in the first quarter of its fiscal year 2021 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted beginning in the first quarter of the Company’s fiscal year 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements and related disclosures.
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Under the new guidance, a lessee will be required to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. This ASU will be effective for the Company in the first quarter of its fiscal year 2020 and early adoption is permitted. The ASU requires adoption based upon a modified retrospective transition approach. However, the FASB has recently proposed guidance that would permit companies not to restate periods priors to adoption. The Company has not yet selected a transition method, has not yet determined whether it will elect early adoption and is currently evaluating the impact of the adoption of this standard on its consolidated financial statements and related disclosures.
In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities (ASU 2016-01). This ASU changes accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, it clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The guidance will become effective for the Company beginning in the first quarter of fiscal year 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted for certain provisions. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements and related disclosures.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is required to be adopted, using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures. The standard will be effective for the Company in the first quarter of its fiscal year 2019. The Company intends to adopt the new standard in the first quarter of fiscal year 2019 using the modified retrospective method. Based upon a preliminary assessment, the Company expects certain portions of its product revenue could be accelerated to reflect transfer of control upon delivery and an element of installation will be deferred until performed. The revenue recognition method for indirect sales and service revenues is expected to be unchanged under the new guidance. The Company also expects to capitalize incremental contract acquisition costs, such as sales commissions, and amortize over the economic life of its product or contractual relationship with the customer. The Company’s current practice is to defer sales commissions until revenue is recognized. The Company currently does not expect the application of this guidance to have a significant impact on its consolidated financial statements; however, the Company’s assessment may change as it continues its evaluation and analysis of this ASU.
Note 3. Supplemental Financial Information
Balance Sheet Components
Financing receivables
A financing receivable is a contractual right to receive money, on demand or on fixed or determinable dates, that is recognized as an asset in the Company’s balance sheet. The Company’s financing receivables, consisting of its accounts receivable with contractual maturities of more than one year and sales-type leases, totaled $8.0 million and $7.4 million at December 31, 2017 and June 30, 2017, respectively, and are included in other assets in the unaudited condensed consolidated balance sheets. The Company evaluates the credit quality of an obligor at lease inception and monitors credit quality over the term of the underlying transactions. The Company performs a credit analysis for all new customers and reviews payment history, current order backlog, financial performance of the customers and other variables that augment or mitigate the inherent credit risk of a transaction. Such variables include the underlying value and liquidity of the collateral, the essential use of the equipment, the term of the lease and the inclusion of credit enhancements, such as guarantees, letters of credit or security deposits. Accounts rated as low risk typically have the equivalent of a Moody’s rating of Baa3 or higher, while accounts rated as moderate risk generally have the equivalent of Ba1 or lower. The Company classifies accounts as high risk when it considers the financing receivable to be impaired or when management believes there is a significant near-term risk of non-payment. As of December 31, 2017, the sales-type lease portion of the financing receivables was rated at a moderate risk. The Company performed an assessment of the allowance for credit losses related to its financing receivables as of December 31, 2017 and June 30, 2017. Based upon such assessment, the Company did not record any adjustment and recorded $0.04 million to the allowance for credit losses related to such financing receivables as of December 31, 2017 and as of June 30, 2017, respectively.
A summary of the Company’s financing receivables is presented as follows (in thousands):
|
December 31, 2017 |
|
Lease |
|
Financed |
|
Total |
| |||
|
Gross |
|
$ |
3,565 |
|
$ |
7,040 |
|
$ |
10,605 |
|
|
Unearned income |
|
(342 |
) |
— |
|
(342 |
) | |||
|
Allowance for credit loss |
|
(39 |
) |
— |
|
(39 |
) | |||
|
Total, net |
|
$ |
3,184 |
|
$ |
7,040 |
|
$ |
10,224 |
|
|
Reported as: |
|
|
|
|
|
|
| |||
|
Current |
|
$ |
741 |
|
$ |
1,492 |
|
$ |
2,233 |
|
|
Non-current |
|
2,443 |
|
5,548 |
|
7,991 |
| |||
|
Total, net |
|
$ |
3,184 |
|
$ |
7,040 |
|
$ |
10,224 |
|
|
June 30, 2017 |
|
Lease |
|
Financed |
|
Total |
| |||
|
Gross |
|
$ |
4,030 |
|
$ |
6,268 |
|
$ |
10,298 |
|
|
Unearned income |
|
(433 |
) |
— |
|
(433 |
) | |||
|
Allowance for credit loss |
|
(39 |
) |
— |
|
(39 |
) | |||
|
Total, net |
|
$ |
3,558 |
|
$ |
6,268 |
|
$ |
9,826 |
|
|
Reported as: |
|
|
|
|
|
|
| |||
|
Current |
|
$ |
720 |
|
$ |
1,677 |
|
$ |
2,397 |
|
|
Non-current |
|
2,838 |
|
4,591 |
|
7,429 |
| |||
|
Total, net |
|
$ |
3,558 |
|
$ |
6,268 |
|
$ |
9,826 |
|
Actual cash collections may differ from the contracted maturities due to early customer buyouts, refinancing, or defaults. Future minimum lease payments to be received as of December 31, 2017 are presented as follows (in thousands):
|
Year Ending June 30, |
|
Amount |
| |
|
2018 (remaining 6 months) |
|
$ |
465 |
|
|
2019 |
|
930 |
| |
|
2020 |
|
930 |
| |
|
2021 |
|
930 |
| |
|
2022 |
|
310 |
| |
|
Total |
|
$ |
3,565 |
|
Inventories
Inventories consisted of the following (in thousands):
|
|
|
December 31, |
|
June 30, |
| ||
|
Raw materials |
|
$ |
42,392 |
|
$ |
38,803 |
|
|
Work-in-process |
|
18,292 |
|
15,471 |
| ||
|
Finished goods |
|
53,125 |
|
50,780 |
| ||
|
Inventories |
|
$ |
113,809 |
|
$ |
105,054 |
|
Property and equipment, net
Property and equipment, net consisted of the following (in thousands):
|
|
|
December 31, |
|
June 30, |
| ||
|
Furniture and fixtures |
|
$ |
4,389 |
|
$ |
4,364 |
|
|
Computer and office equipment |
|
11,717 |
|
11,802 |
| ||
|
Software |
|
11,420 |
|
11,457 |
| ||
|
Leasehold improvements |
|
23,239 |
|
23,164 |
| ||
|
Machinery and equipment |
|
45,988 |
|
48,742 |
| ||
|
Construction in progress |
|
4,687 |
|
3,533 |
| ||
|
|
|
101,440 |
|
103,062 |
| ||
|
Less: Accumulated depreciation |
|
(78,839 |
) |
(80,000 |
) | ||
|
Property and equipment, net |
|
$ |
22,601 |
|
$ |
23,062 |
|
Depreciation expense related to property and equipment for the three and six months ended December 31, 2017 was $2.5 million and $4.9 million, respectively. Depreciation expense related to property and equipment for the three and six months ended December 31, 2016 was $2.6 million and $5.3 million, respectively.
Accumulated Other Comprehensive Income (Loss)
The changes in accumulated other comprehensive income (loss) are excluded from earnings and reported as a component of stockholders’ equity. The foreign currency translation adjustment results from those subsidiaries not using the U.S. Dollar as their functional currency since the majority of their economic activities are primarily denominated in their applicable local currency. Accordingly, all assets and liabilities related to these operations are translated to the U.S. Dollar at the current exchange rates at the end of each period. Revenues and expenses are translated at average exchange rates in effect during the period.
The components of accumulated other comprehensive income (loss) in the equity section of the balance sheets are as follows (in thousands):
|
|
|
December 31, |
|
June 30, |
| ||
|
Net unrealized gain (loss) on short-term investments |
|
$ |
35 |
|
$ |
(89 |
) |
|
Cumulative foreign currency translation adjustment |
|
1,712 |
|
1,154 |
| ||
|
Defined benefit pension obligation |
|
(1,117 |
) |
(1,117 |
) | ||
|
Accumulated other comprehensive income (loss) |
|
$ |
630 |
|
$ |
(52 |
) |
Note 4. Goodwill and Intangible Assets
Goodwill
Activity related to goodwill consisted of the following (in thousands):
|
|
|
December 31, |
|
June 30, |
| ||
|
Balance at the beginning of the period |
|
$ |
57,812 |
|
$ |
57,848 |
|
|
Currency translation |
|
98 |
|
(36 |
) | ||
|
Balance at the end of the period |
|
$ |
57,910 |
|
$ |
57,812 |
|
In the second quarter of fiscal 2018, the Company performed its annual goodwill impairment test. Based on this analysis, the Company determined that there was no impairment to goodwill. The Company will continue to monitor its recorded goodwill for indicators of impairment.
Intangible Assets
The Company’s carrying amount of acquired intangible assets, net, is as follows (in thousands):
|
|
|
|
|
December 31, 2017 |
|
June 30, 2017 |
| ||||||||||||||
|
|
|
|
|
Gross |
|
|
|
|
|
Gross |
|
|
|
|
| ||||||
|
|
|
Useful Lives |
|
Carrying |
|
Accumulated |
|
Net |
|
Carrying |
|
Accumulated |
|
Net |
| ||||||
|
|
|
(in years) |
|
Amount |
|
Amortization |
|
Amount |
|
Amount |
|
Amortization |
|
Amount |
| ||||||
|
Patent license |
|
7 |
|
$ |
1,000 |
|
$ |
(107 |
) |
$ |
893 |
|
$ |
1,000 |
|
$ |
(36 |
) |
$ |
964 |
|
The Company did not identify any triggering events that would indicate potential impairment of its definite-lived intangible and long-lived assets as of December 31, 2017 and June 30, 2017.
Amortization expense related to intangible assets for the three and six months ended December 31, 2017 was $0.04 million and $0.07 million, respectively. Amortization expense related to intangible assets for the three and six months ended December 31, 2016 was $2.0 million and $4.0 million, respectively.
The estimated future amortization expense of acquired intangible assets as of December 31, 2017 is as follows (in thousands):
|
Year Ending June 30, |
|
Amount |
| |
|
2018 (remaining 6 months) |
|
$ |
72 |
|
|
2019 |
|
143 |
| |
|
2020 |
|
143 |
| |
|
2021 |
|
143 |
| |
|
2022 |
|
143 |
| |
|
Thereafter |
|
249 |
| |
|
|
|
$ |
893 |
|
Note 5. Investments
The Company considers all highly liquid investments held at major banks, certificates of deposit and other securities with original maturities of three months or less to be cash equivalents.
The Company classifies all of its investments as available-for-sale at the time of purchase because management intends that these investments are available for current operations and includes these investments on its balance sheet as short-term investments. Investments with original maturities longer than three months include commercial paper, U.S. agency securities, non-U.S. government securities and investment-grade corporate debt securities. Investments classified as available-for-sale are recorded at fair market value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity. Realized gains and losses are recorded based on specific identification of each security’s cost basis.
The Company held a total of eight investments that were in an unrealized loss position as of December 31, 2017 and June 30, 2017, respectively. The Company reviews its investments quarterly to identify and evaluate investments that have an indication of possible impairment. Gross realized gains and losses were insignificant for the six months ended December 31, 2017 and the year ended June 30, 2017. In January 2018, the Company sold eight investments for proceeds of $23.9 million, realizing an insignificant loss on the sale of investments.
Contractual maturities of available-for-sale securities at December 31, 2017 were as follows (in thousands):
|
|
|
December 31, 2017 |
| ||||
|
|
|
Amortized |
|
Estimated |
| ||
|
|
|
Cost |
|
Fair Value |
| ||
|
Due in 1 year or less |
|
$ |
24,482 |
|
$ |
24,516 |
|
The following table summarizes the available-for-sale debt securities that were in a continuous unrealized loss position, but were not deemed to be other-than-temporarily impaired (in thousands):
|
|
|
Less Than 12 Months |
|
12 Months or Greater |
|
Total |
| ||||||||||||
|
|
|
Gross |
|
|
|
Gross |
|
|
|
Gross |
|
|
| ||||||
|
|
|
Unrealized |
|
Estimated |
|
Unrealized |
|
Estimated |
|
Unrealized |
|
Estimated |
| ||||||
|
December 31, 2017 |
|
Losses |
|
Fair Value |
|
Losses |
|
Fair Value |
|
Losses |
|
Fair Value |
| ||||||
|
U. S. government agency securities |
|
$ |
(81 |
) |
$ |
23,868 |
|
$ |
— |
|
$ |
— |
|
$ |
(81 |
) |
$ |
23,868 |
|
|
June 30, 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
U. S. government agency securities |
|
$ |
(31 |
) |
$ |
11,970 |
|
$ |
(58 |
) |
$ |
11,939 |
|
$ |
(89 |
) |
$ |
23,909 |
|
|
Total |
|
$ |
(31 |
) |
$ |
11,970 |
|
$ |
(58 |
) |
$ |
11,939 |
|
$ |
(89 |
) |
$ |
23,909 |
|
Note 6. Derivative Financial Instruments
The Company manages some of its foreign currency risk through the purchase of foreign currency forward contracts that hedge against the short-term effect of currency fluctuations. These foreign currency forward contracts have a monthly maturity that mitigates the effect of rate fluctuations on certain local currency denominated intercompany balances, cash, and customer receivables.
The Company does not use derivative financial instruments for speculative or trading purposes. These forward contracts are not designated as hedging instruments for accounting purposes. Principal hedged currencies include the Euro, Japanese Yen, Swiss Franc, and U.S. Dollar. There were no outstanding foreign currency forward contracts at the end of December 31, 2017 and June 30, 2017.
The following table provides information about gains (losses) associated with the Company’s derivative financial instruments (in thousands):
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
|
December 31, |
|
December 31, |
| ||||||||
|
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
| ||||
|
Foreign currency exchange loss on foreign contracts |
|
$ |
(2,679 |
) |
$ |
(604 |
) |
$ |
(2,438 |
) |
$ |
(1,167 |
) |
|
Foreign currency transactions gain (loss) |
|
2,521 |
|
(48 |
) |
2,525 |
|
84 |
| ||||
Note 7. Fair Value Measurements
Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy contains three levels of inputs that may be used to measure fair value, as follows:
Level 1— Unadjusted quoted prices that are available in active markets for the identical assets or liabilities at the measurement date.
Level 2— Other observable inputs available at the measurement date, other than quoted prices included in Level 1, either directly or indirectly, including:
· Quoted prices for similar assets or liabilities in active markets;
· Quoted prices for identical or similar assets in non-active markets;
· Inputs other than quoted prices that are observable for the asset or liability; and
· Inputs that are derived principally from or corroborated by other observable market data.
Level 3— Unobservable inputs that cannot be corroborated by observable market data and require the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions.
The Company’s Level 1 assets include institutional money-market funds that are classified as cash equivalents, which are valued primarily using quoted market prices in active markets for identical assets. The Company’s Level 2 assets include its U.S. government agency securities and its corporate securities as the market inputs used to value these instruments consist of market yields, reported trades and broker/dealer quotes, which are corroborated with observable market data.
The tables below set forth, by level, the Company’s financial assets that were accounted for at fair value (in thousands):
|
|
|
December 31, 2017 |
| |||||||||||||
|
|
|
|
|
|
|
|
|
Estimated Fair Value |
| |||||||
|
|
|
|
|
Gross |
|
Gross |
|
Cash and |
|
|
| |||||
|
|
|
Amortized |
|
Unrealized |
|
Unrealized |
|
Cash |
|
Short-term |
| |||||
|
|
|
Cost |
|
Gains |
|
Losses |
|
Equivalents |
|
Investments |
| |||||
|
Cash |
|
$ |
77,767 |
|
$ |
— |
|
$ |
— |
|
$ |
77,767 |
|
$ |
— |
|
|
Level 1 |
|
|
|
|
|
|
|
|
|
|
| |||||
|
Money market funds |
|
1,742 |
|
— |
|
— |
|
1,742 |
|
— |
| |||||
|
Level 2 |
|
|
|
|
|
|
|
|
|
|
| |||||
|
U.S. government agency securities |
|
17,999 |
|
— |
|
(75 |
) |
— |
|
17,924 |
| |||||
|
U. S. treasury bills |
|
5,950 |
|
|
|
(6 |
) |
|
|
5,944 |
| |||||
|
Corporate securities |
|
533 |
|
115 |
|
|
|
|
|
648 |
| |||||
|
Total |
|
$ |
103,991 |
|
$ |
115 |
|
$ |
(81 |
) |
$ |
79,509 |
|
$ |
24,516 |
|
|
|
|
June 30, 2017 |
| |||||||||||||
|
|
|
|
|
|
|
|
|
Estimated Fair Value |
| |||||||
|
|
|
|
|
Gross |
|
Gross |
|
Cash and |
|
|
| |||||
|
|
|
Amortized |
|
Unrealized |
|
Unrealized |
|
Cash |
|
Short-term |
| |||||
|
|
|
Cost |
|
Gains |
|
Losses |
|
Equivalents |
|
Investments |
| |||||
|
Cash |
|
$ |
70,515 |
|
$ |
— |
|
$ |
— |
|
$ |
70,515 |
|
$ |
— |
|
|
Level 1 |
|
|
|
|
|
|
|
|
|
|
| |||||
|
Money market funds |
|
1,569 |
|
— |
|
— |
|
1,569 |
|
— |
| |||||
|
Level 2 |
|
|
|
|
|
|
|
|
|
|
| |||||
|
U.S. government agency securities |
|
23,998 |
|
— |
|
(89 |
) |
— |
|
23,909 |
| |||||
|
Total |
|
$ |
96,082 |
|
$ |
— |
|
$ |
(89 |
) |
$ |
72,084 |
|
$ |
23,909 |
|
Liabilities That Are Measured at Fair Value on a Nonrecurring Basis
The debt is measured on a non-recurring basis using Level 2 inputs based upon observable inputs of the Company’s underlying stock price and the time value of the conversion option, since an observable quoted price of the 3.50% Convertible Notes (as defined below), the 3.50% Series A Convertible Notes (as defined below) and the 3.75% Convertible Notes (as defined below) (collectively the “Notes”) are not readily available. The carrying value of the Revolving Credit Facility (as defined below) and the Term Loan (as defined below) (collectively the “Credit Facilities”, together with the Notes, “Debt”) approximate its estimated fair value as these borrowings have a variable rate structure that is based on a market observable interest rate that resets periodically. The Credit Facilities are classified as Level 2 within the fair value hierarchy.
The following table summarizes the carrying value and estimated fair value of all Debt (in thousands):
|
|
|
December 31, 2017 |
|
June 30, 2017 |
| ||||||||
|
|
|
Carrying Value |
|
Fair Value |
|
Carrying Value |
|
Fair Value |
| ||||
|
3.50% Convertible Notes |
|
$ |
12,976 |
|
$ |
13,260 |
|
$ |
44,099 |
|
$ |
48,146 |
|
|
3.50% Series A Convertible Notes |
|
26,475 |
|
26,818 |
|
68,924 |
|
74,982 |
| ||||
|
3.75% Convertible Notes |
|
67,819 |
|
88,400 |
|
— |
|
— |
| ||||
|
Revolving Credit Facility |
|
24,983 |
|
24,983 |
|
51,548 |
|
51,548 |
| ||||
|
Term Loan |
|
37,623 |
|
37,623 |
|
— |
|
— |
| ||||
|
Total |
|
$ |
169,876 |
|
$ |
191,084 |
|
$ |
164,571 |
|
$ |
174,676 |
|
Note 8. Commitments and Contingencies
Litigation
From time to time, the Company is involved in legal proceedings arising in the ordinary course of its business. The Company records a provision for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated. Currently, management believes the Company does not have any probable and estimable losses related to legal proceedings and claims. Although occasional adverse decisions or settlements may occur, management does not believe that an adverse determination with respect to any of these claims would individually or in the aggregate materially and adversely affect the Company’s financial condition or operating results. Litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company’s control. Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related to legal matters that could have a material impact on its results of operations, financial position and cash flows.
Software License Indemnity
Under the terms of the Company’s software license agreements with its customers, the Company agrees that in the event the software sold infringes upon any patent, copyright, trademark, or any other proprietary right of a third-party, it will indemnify its customer licensees against any loss, expense, or liability from any damages that may be awarded against them. The Company includes this infringement indemnification in all of its software license agreements and selected managed services arrangements. In the event the customer cannot use the software or service due to infringement and the Company cannot obtain the right to use, replace or modify the license or service in a commercially feasible manner so that it no longer infringes, then the Company may terminate the license and provide the customer a refund of the fees paid by the customer for the infringing license or service. The Company has not recorded any liability associated with this indemnification, as it is not aware of any pending or threatened actions that represent probable losses as of December 31, 2017.
Note 9. Debt
3.50% Convertible Senior Notes due February 2018
In February 2013, the Company issued 3.50% Convertible Senior Notes due 2018 (the “3.50% Convertible Notes”) under an indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Holders of the 3.50% Convertible Notes may convert their notes at any time until the close of the business day immediately preceding the maturity date. The 3.50% Convertible Notes are convertible into common stock of the Company at an initial conversion rate equal to 187.6877 shares of common stock per $1,000 principal amount, which is equivalent to a conversion price of approximately $5.33 per share of common stock, subject to adjustment. The 3.50% Convertible Notes bear interest at a rate of 3.50% per year, payable semi-annually in arrears in cash on February 1 and August 1 of each year. The 3.50% Convertible Notes has a maturity date of February 1, 2018, unless earlier repurchased, redeemed or converted, thus it has been classified as short-term debt on the Company’s unaudited condensed consolidated balance sheets.
Holders of the 3.50% Convertible Notes who convert their notes in connection with a “make-whole fundamental change,” as defined in the indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a “fundamental change,” as defined in the indenture, holders of the 3.50% Convertible Notes may require the Company to purchase all or a portion of their 3.50% Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of 3.50% Convertible Notes, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date. As of December 31, 2017, approximately $13.0 million aggregate principal amount was outstanding. On February 1, 2018, the 3.50% Convertible Notes were settled in full. Refer to Note 14. Subsequent Events to our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
3.50% Series A Convertible Senior Notes due February 2018
In April 2014, the Company issued 3.50% Series A Convertible Senior Notes due 2018 (the “3.50% Series A Convertible Notes”) under an indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Holders of the 3.50% Series A Convertible Notes may convert their notes at any time on or after November 1, 2017 until the close of business on the business day immediately preceding the maturity date. The initial conversion rate is 187.6877 shares of the Company’s common stock per $1,000 principal amount, which represents an initial conversion price of approximately $5.33 per share of the Company’s common stock. The 3.50% Series A Convertible Notes generally have the same interest rate, maturity and other terms as the 3.50% Convertible Notes, except that the 3.50% Series A Convertible Notes are convertible into cash, shares of the Company’s common stock or a combination of cash and shares of common stock, at the Company’s option.
Holders of the 3.50% Series A Convertible Notes who convert their notes in connection with a “make-whole fundamental change,” as defined in the indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a “fundamental change,” as defined in the indenture, holders of the 3.50% Series A Convertible Notes may require the Company to purchase all or a portion of their 3.50% Series A Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 3.50% Series A Convertible Notes, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date. The 3.50% Series A Convertible Notes has a maturity date of February 1, 2018; thus, it has been classified as short-term debt on the Company’s unaudited condensed consolidated balance sheets. As of December 31, 2017, approximately $26.6 million aggregate principal amount was outstanding. On February 1, 2018, the 3.50% Series A Convertible Notes were repaid in full. Refer to Note 14. Subsequent Events to our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
3.75% Convertible Senior Notes due July 2022
In August 2017, the Company issued $85.0 million aggregate principal amount of its 3.75% Convertible Senior Notes due 2022 (the “3.75% Convertible Notes”) under an indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. $53.0 million aggregate principal amount of the 3.75% Convertible Notes were issued to certain holders of the Company’s outstanding 3.50% Convertible Notes and 3.50% Series A Convertible Notes (together, the “Existing Notes”) in exchange for approximately $47.0 million aggregate principal amount of the Existing Notes (the “Exchange”) and $32.0 million aggregate principal amount of the 3.75% Convertible Notes were issued to certain other qualified new investors for cash. The net proceeds of the cash issuance were used to repurchase approximately $28.0 million of Existing Notes (the “Repurchase”).
Holders of the 3.75% Convertible Notes may convert their notes at any time on or after April 15, 2022 until the close of the business day immediately preceding the maturity date. Prior to April 15, 2022, holders of the 3.75% Convertible Notes may convert their notes only under certain circumstances
Upon conversion, the Company will have the right to pay cash, or deliver shares of common stock of the Company or a combination thereof, at the Company’s election. The initial conversion rate is 174.8252 shares of the Company’s common stock per $1,000 principal amount (which represents an initial conversion price of approximately $5.72 per share of the Company’s common stock). The conversion rate, and thus the conversion price, is subject to adjustment as further described below.
Holders of the 3.75% Convertible Notes who convert their notes in connection with a “make-whole fundamental change,” as defined in the indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a “fundamental change,” as defined in the indenture, holders of the 3.75% Convertible Notes may require the Company to purchase all or a portion of their note at a fundamental change repurchase price equal to 100% of the principal amount of the 3.75% Convertible Notes, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date. As of December 31, 2017, approximately $67.8 million aggregate principal amount was outstanding.
Revolving Credit Facility
On June 14, 2017, the Company entered into a credit and security agreement with a lender (the “Credit Agreement”). The Credit Agreement provides the Company with a revolving credit facility in the initial amount of $52.0 million (the “Revolving Credit Facility”). Availability for borrowings under the Revolving Credit Facility is subject to a borrowing base that is calculated as a function of the value of the Company’s eligible accounts receivable and eligible inventory, and the Company is required to maintain a minimum drawn balance of at least 30% of such availability. Interest on the borrowings under the Revolving Credit Facility is payable monthly in arrears at an annual interest rate of reserve-adjusted, 90-day LIBOR plus 4.50% and had initial maturity date of June 14, 2021.
In December 2017, concurrently with the Term Loan Agreement described below, the Company entered into an amendment to the Credit Agreement (the “Amendment” and, collectively with the Credit Agreement, the “Amended Credit Agreement”). The Amendment reduced the maximum borrowings under the Revolving Credit Facility to $32.0 million and extended the maturity date of the Revolving Credit Facility to December 15, 2022.
The Amended Credit Agreement contains restrictions and covenants applicable to the Company. Among other requirements, the Company may not permit the Fixed Charge Coverage Ratio (as defined in the Amended Credit Agreement) to be less than a certain specified ratio for each fiscal quarter during the term of the Revolving Credit Facility. In addition, the Amended Credit Agreement contains customary restrictive covenants that limit, among other things, the ability of the Company and its subsidiaries to (i) incur additional indebtedness, (ii) incur liens on their property, (iii) pay dividends or make other distributions, (iv) sell their assets, (v) make certain loans or investments, (vi) merge or consolidate, (vii) voluntarily repay or prepay certain indebtedness and (viii) enter into transactions with affiliates, in each case subject to certain exceptions. The Company was in compliance with the covenants as of December 31, 2017. As of December 31, 2017, approximately $25.0 million aggregate principal amount was outstanding under the Revolving Credit Facility.
Term Loan
In December 2017, the Company entered into a credit and security agreement with a lender (the “Term Loan Agreement”). The Term Loan Agreement provides for an initial term loan of $40.0 million with an additional tranche of $20.0 million available through December 31, 2018, if specified conditions are met (the “Term Loan”). In connection with the Amendment, the Company used a portion of the net proceeds from the initial advance to repay a portion of the outstanding borrowings under the Revolving Credit Facility. Interest on the Term Loan is payable monthly in arrears at an annual interest rate of 6.75% plus 90-day LIBOR. The Term Loan Agreement matures December 15, 2022 and, if prepaid, has fees equal to 3%, 2%, and 1% of the prepayment amount if such termination occurs within the first year, the second year, and the third year of funding, respectively. The term of the loan is 60 months with interest only for the first 24 months followed by straight-line amortization of principal for the remaining months. In addition, the Company will pay an annual administrative fee of 0.25% and a final payment of 4.0% of the Term Loan amount.
The Term Loan issuance costs of $2.0 million, including a portion of the unamortized offering costs of Revolving Credit Facility, and a $2.0 million debt discount were deferred and being amortized over the 5-year term of the Term Loan.
The following table presents the carrying value of all Debt (in thousands):
|
As of December 31, 2017 |
|
Revolving |
|
3.50% Convertible |
|
3.50% Series A |
|
3.75% |
|
Term Loan |
|
Total |
| ||||||
|
Carrying amount of equity conversion component |
|
$ |
— |
|
$ |
— |
|
$ |
2,806 |
|
$ |
14,650 |
|
$ |
— |
|
$ |
17,456 |
|
|
Principal amount of the Notes |
|
$ |
24,983 |
|
$ |
13,000 |
|
$ |
26,552 |
|
$ |
85,000 |
|
$ |
40,000 |
|
$ |
189,535 |
|
|
Unamortized debt costs |
|
— |
|
(24 |
) |
— |
|
(3,649 |
) |
(2,002 |
) |
(5,675 |
) | ||||||
|
Unamortized debt discount |
|
— |
|
— |
|
(77 |
) |
(13,532 |
) |
(375 |
) |
(13,984 |
) | ||||||
|
Net carrying amount |
|
$ |
24,983 |
|
$ |
12,976 |
|
$ |
26,475 |
|
$ |
67,819 |
|
$ |
37,623 |
|
$ |
169,876 |
|
|
Reported as: |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Short-term debt |
|
|
|
|
|
|
|
|
|
|
|
$ |
39,451 |
|
|
Long-term debt |
|
|
|
|
|
|
|
|
|
|
|
130,425 |
| |
|
Total debt |
|
|
|
|
|
|
|
|
|
|
|
$ |
169,876 |
|
|
As of June 30, 2017 |
|
Revolving |
|
3.50% Convertible |
|
3.50% Series A |
|
Total |
| ||||
|
Carrying amount of equity conversion component |
|
$ |
— |
|
$ |
— |
|
$ |
7,844 |
|
$ |
7,844 |
|
|
Principal amount of the Notes |
|
$ |
51,548 |
|
$ |
44,654 |
|
$ |
70,346 |
|
$ |
166,548 |
|
|
Unamortized debt costs |
|
— |
|
(555 |
) |
— |
|
(555 |
) | ||||
|
Unamortized debt discount |
|
— |
|
— |
|
(1,422 |
) |
(1,422 |
) | ||||
|
Net carrying amount |
|
$ |
51,548 |
|
$ |
44,099 |
|
$ |
68,924 |
|
$ |
164,571 |
|
|
Reported as: |
|
|
|
|
|
|
|
|
| |
|
Short-term debt |
|
|
|
|
|
|
|
$ |
113,023 |
|
|
Long-term debt |
|
|
|
|
|
|
|
51,548 |
| |
|
Total debt |
|
|
|
|
|
|
|
$ |
164,571 |
|
A summary of interest expense on the Debt is as follows (in thousands):
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
|
December 31, |
|
December 31, |
| ||||||||
|
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
| ||||
|
Interest expense related to contractual interest coupon |
|
$ |
2,427 |
|
$ |
2,339 |
|
$ |
4,836 |
|
$ |
4,870 |
|
|
Interest expense related to amortization of debt discount |
|
865 |
|
640 |
|
1,727 |
|
1,456 |
| ||||
|
Interest expense related to amortization of debt issuance costs |
|
420 |
|
379 |
|
868 |
|
782 |
| ||||
|
|
|
$ |
3,712 |
|
$ |
3,358 |
|
$ |
7,431 |
|
$ |
7,108 |
|
Note 10. Share-Based Compensation
The following table presents details of share-based compensation expenses by functional line item (in thousands):
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
|
December 31, |
|
December 31, |
| ||||||||
|
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
| ||||
|
Cost of revenue |
|
$ |
475 |
|
$ |
418 |
|
$ |
968 |
|
$ |
942 |
|
|
Research and development |
|
634 |
|
501 |
|
1,265 |
|
1,164 |
| ||||
|
Selling and marketing |
|
530 |
|
686 |
|
367 |
|
1,308 |
| ||||
|
General and administrative |
|
1,799 |
|
1,309 |
|
3,270 |
|
2,973 |
| ||||
|
|
|
$ |
3,438 |
|
$ |
2,914 |
|
$ |
5,870 |
|
$ |
6,387 |
|
Note 11. Net Loss Per Common Share
The Company reports both basic and diluted loss per share, which is based on the weighted average number of common shares outstanding during the period.
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per common share follows (in thousands):
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
|
December 31, |
|
December 31, |
| ||||||||
|
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
| ||||
|
Numerator: |
|
|
|
|
|
|
|
|
| ||||
|
Net loss used to compute basic and diluted loss per share |
|
$ |
(4,719 |
) |
$ |
(9,369 |
) |
$ |
(14,101 |
) |
$ |
(19,295 |
) |
|
Denominator: |
|
|
|
|
|
|
|
|
| ||||
|
Weighted average shares used to compute basic and diluted loss per share |
|
84,586 |
|
82,328 |
|
84,167 |
|
81,952 |
| ||||
The potentially dilutive shares of the Company’s common stock resulting from the assumed exercise of outstanding stock options, the settlement of vested Restricted Stock Units (RSU), Market Stock Units (MSU) and Performance Stock Units (PSU), and the purchase of shares under the Company’s Employee Stock Purchase Program (ESPP), as determined under the treasury stock method, are excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive. Additionally, the 3.50% Convertible Notes is included in the calculation of diluted net income per share only if their inclusion is dilutive.
The following table sets forth all potentially dilutive securities excluded from the computation in the table above because their effect would have been anti-dilutive (in thousands):
|
|
|
As of December 31, |
| ||
|
|
|
2017 |
|
2016 |
|
|
Stock options |
|
2,799 |
|
2,850 |
|
|
RSUs, PSUs and MSUs |
|
5,204 |
|
5,622 |
|
|
3.50% Convertible Notes |
|
2,439 |
|
8,378 |
|
|
|
|
10,442 |
|
16,850 |
|
3.75% Convertible Notes and 3.50% Series A Convertible Notes—Diluted Share Impact
The 3.75% Convertible Notes and the 3.50% Series A Convertible Notes have an optional physical (share), cash or combination settlement feature and contain certain conditional conversion features. Due to the optional cash settlement feature and management’s intent to settle the principal amount thereof in cash, the shares of our common stock issuable upon conversion of the outstanding principal amount of the 3.75% Convertible Notes and the 3.50% Series A Convertible Notes as of December 31, 2017, totaling approximately 19.8 million shares of our common stock, were not included in the basic and diluted net loss per common share table above.
Note 12. Segment Information
The Company operates in one reportable segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy and radiosurgery for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset based metrics.
The following tables present net revenue and long-lived asset information based on geographic region. Net revenue is based on the destination of the shipments and long-lived assets are based on the physical location of the assets (in thousands):
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
|
December 31, |
|
December 31, |
| ||||||||
|
Net Revenue |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
| ||||
|
Americas |
|
$ |
37,754 |
|
$ |
39,183 |
|
$ |
73,777 |
|
$ |
79,825 |
|
|
Europe, Middle East, India and Africa |
|
32,006 |
|
25,638 |
|
67,154 |
|
46,920 |
| ||||
|
Asia-Pacific |
|
30,569 |
|
22,681 |
|
50,348 |
|
47,263 |
| ||||
|
Total |
|
$ |
100,329 |
|
$ |
87,502 |
|
$ |
191,279 |
|
$ |
174,008 |
|
|
|
|
December 31, |
|
June 30, |
| ||
|
Property and equipment, net |
|
2017 |
|
2017 |
| ||
|
Americas |
|
$ |
18,108 |
|
$ |
18,435 |
|
|
Europe, Middle East, India and Africa |
|
763 |
|
730 |
| ||
|
Asia-Pacific |
|
3,730 |
|
3,897 |
| ||
|
Total |
|
$ |
22,601 |
|
$ |
23,062 |
|
Note 13. Income Tax
On a quarterly basis, the Company provides for income taxes based upon an estimated annual effective income tax rate. The Company recognized an income tax benefit of less than $0.1 million and an income tax expense of $0.7 million for the three and six months ended December 31, 2017, respectively. The Company recognized an income tax expense of $0.4 million and an income tax benefit of $0.2 million for the three and six months ended December 31, 2016, respectively.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (“Tax Act”) was signed into law. The Company believes the impact of the inclusion of accumulated post-1986 foreign earnings on which U.S. income tax is currently deferred to a one-time transition tax on December 31, 2017 would not be material to the Company. The measurement of the transition tax liability requires extensive effort on the calculation of the foreign earnings and profit on a cumulative basis. The Company has made reasonable efforts to determine that there would be no material financial impact on this one-time transition tax as the Company believes its existing tax attributes can be used to offset the transition tax without limitation, but an election is available to not claim the net operating loss deduction against the mandatory foreign earnings inclusion at December 31, 2017.
Under ASC 740, Accounting for Income Taxes, the enactment of the Tax Act also requires companies, to recognize the effects of changes in tax laws and rates on deferred tax assets and liabilities and the retroactive effects of changes in tax laws in the period in which the new legislation is enacted. There is no further change to its assertion on maintaining a full valuation allowance against its U.S. deferred tax assets. The Company’s gross deferred tax assets will be revalued from 35% to 21% with a corresponding offset to the valuation allowance and any potential other taxes arising due to the Tax Act will result in reductions to its net operating loss carryforward and valuation allowance. Deferred tax assets of approximately $174.0 million will be revalued to approximately $117.0 million with a corresponding decrease to the Company’s valuation allowance. The Company will continue to analyze the Tax Act to assess the full effects on its financial results, including disclosures, for our fiscal year ending June 30, 2018.
Note 14. Subsequent Events
3.50% Convertible Notes
On January 30, 2018, the Company entered into exchange agreements with the holders of the 3.50% Convertible Notes (the “Exchange Agreements”), which allowed the Company to settle the $13.0 million outstanding principal amount of 3.50% Convertible Notes and accrued interest in cash at maturity, and any excess equity value over the original conversion price in shares (the “Exchange Shares”) to be delivered in February 2018. The Company also agreed to pay a $0.3 million exchange premium in the form of shares of the Company’s common stock (the “Exchange Premium” and together with the Exchange Shares, the “Share Consideration”). The Share Consideration is determined based on a prescribed formula in the Exchange Agreements.
On February 1, 2018, pursuant to the Exchange Agreements, the Company paid $13.2 million in cash to settle outstanding principal and accrued interest with respect to the 3.50% Convertible Notes. The total number of shares to be delivered for the Share Consideration will be determined following the three-day averaging period specified in the Exchange Agreement.
3.50% Series A Convertible Notes
On February 1, 2018, the Company paid $27.0 million in cash and issued an insignificant number of shares of common stock to settle the outstanding principal amount and accrued interest under the 3.50% Series A Convertible Notes upon maturity.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition as of December 31, 2017 and results of operations for the three and six months ended December 31, 2017 and 2016 should be read together with our unaudited condensed consolidated financial statements and related notes included in this report. Statements made in this Form 10-Q report that are not statements of historical fact are forward-looking statements that are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this report relate, but are not limited, to: our future results of operations and financial position, including the sufficiency of cash resources and expected cash flows to fund future operations, including the next 12 months; our backlog and expectations regarding age-outs, cancellations of contracts and foreign currency impacts; the anticipated drivers of our future capital requirements; our expectations regarding the improvements in efficiency made by the multi-leaf collimator, or InCise MLC, on the CyberKnife Systems, and its impact on our business; our expectations regarding the factors that will impact long-term success, sales, competitive positioning and long-term success for our CyberKnife and TomoTherapy Systems, including Radixact Systems; our belief that TomoTherapy and Radixact Systems offer clinicians and patients significant benefits over other radiation therapy systems in the market; the anticipated risks associated with our foreign operations and fluctuations in the U.S. Dollar and foreign currencies as well as our ability to mitigate such risks; our plans related to cash held by our foreign subsidiaries; our expectations related to the effects of the Tax Cuts and Jobs Act of 2017 on the Company; the sufficiency of our cash, cash flow equivalents and investments to meet our anticipated cash needs for working capital and capital expenditures and our business strategy, plans and objectives. Forward-looking statements generally can be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “may,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of our assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, those discussed in this quarterly report, in particular under the heading “Risk Factors” in Part II, Item 1A as well as the risks detailed in Part I, Item 1A of our annual report on Form 10-K for fiscal year 2017, and other filings we make with the Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements are made and are based on information available to us at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
In this report, “Accuray,” the “Company,” “we,” “us,” and “our” refer to Accuray Incorporated and its subsidiaries.
Overview
Products and Markets
We are a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. Our leading-edge technologies, the CyberKnife and TomoTherapy Systems, including Radixact Systems, the next generation TomoTherapy System platform, are designed to deliver advanced radiation therapy including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy tailored to the specific needs of each patient. The CyberKnife and TomoTherapy Systems are complementary offerings serving largely separate patient populations treated by the same medical specialty, radiation oncology, with advanced capabilities that offer increased treatment flexibility to meet the needs of an expanding patient population including patients requiring retreatment with radiation therapy. We also offer comprehensive software solutions to enable and enhance the precise and efficient radiosurgery and radiotherapy treatment with our CyberKnife and TomoTherapy Systems. In addition to these products, we also provide services, which include post-contract customer support (warranty period services and post warranty services), installation services, training and other professional services.
The CyberKnife Systems
The CyberKnife Systems are robotic systems designed to deliver radiosurgery treatments to cancer tumors anywhere in the body. The CyberKnife Systems are the only dedicated, full-body robotic radiosurgery systems on the market. Radiosurgery is an alternative to traditional surgery for tumors and is performed on an outpatient basis in one to five treatment sessions. It enables the treatment of patients who typically might not otherwise be treated with radiation, who may not be good candidates for surgery, or who desire non-surgical treatments. The use of radiosurgery with CyberKnife Systems to treat tumors throughout the body has grown significantly in recent years, but currently only a small portion of the patients who develop tumors treatable with CyberKnife Systems are treated with these systems. A determination of when it may or may not be appropriate to use a CyberKnife System for treatment is at the discretion of the treating physician and depends on the specific patient. However, the CyberKnife Systems are generally not
used to treat (1) very large tumors, which are considerably wider than the radiation beam that can be delivered by CyberKnife Systems, (2) diffuse wide-spread disease, as is often the case for late stage cancers, because they are not localized (though CyberKnife Systems might be used to treat a focal area of the disease) and (3) systemic diseases, like leukemia and lymphoma, which are not localized to an organ, but rather involve cells throughout the body.
Our CyberKnife M6 Series Systems have the option of: fixed collimator, Iris Variable Aperture Collimator and/or multi-leaf collimator, or InCise MLC. The InCise MLC is designed specifically for the M6 Series. With the InCise MLC, clinicians can deliver the same precise radiosurgery treatments they have come to expect with the CyberKnife System, faster and for a wider range of tumor types than prior CyberKnife systems. The InCise MLC makes it faster and more efficient to treat a wider range of tumor types with the CyberKnife M6 Series System, including larger tumors and those with multiple sites of disease.
We believe the long term success of the CyberKnife Systems is dependent on a number of factors including the following:
· Continued adoption of our CyberKnife M6 Series Systems;
· Greater awareness among doctors and patients of the benefits of radiosurgery conducted with the CyberKnife Systems;
· Continued evolution in clinical studies demonstrating the safety, efficacy and other benefits of using the CyberKnife Systems to treat tumors in various parts of the body;
· Change in medical practice leading to utilization of stereotactic body radiosurgery more regularly as an alternative to surgery or other treatments;
· Continued advances in our technology that improve the quality of treatments and ease of use of the CyberKnife Systems;
· Receipt of regulatory approvals in various countries which are expected to improve access to radiosurgery with the CyberKnife Systems in such countries;
· Medical insurance reimbursement policies that cover CyberKnife System treatments; and
· Our ability to expand sales of CyberKnife Systems in countries throughout the world where we do not currently sell or have not historically sold a significant number of CyberKnife Systems.
TomoTherapy Systems, including Radixact Systems, the next generation TomoTherapy System
The TomoTherapy Systems are advanced, fully integrated and versatile radiation therapy systems for the treatment of a wide range of cancer types. The TomoTherapy Systems are specifically designed for image-guided intensity-modulated radiation therapy (IG-IMRT). The TomoTherapy Systems include the TomoTherapy H Series Systems with configurations of TomoH, TomoHD and TomoHDA. Based on a CT scanner platform, the systems provide continuous delivery of radiation from 360 degrees around the patient, or delivery from clinician-specified beam angles. These unique features, combined with daily 3D image guidance, enable physicians to deliver highly accurate, individualized dose distributions which precisely conform to the shape of the patient’s tumor while minimizing dose to normal, healthy tissue, resulting in fewer side effects for the patient. The TomoTherapy Systems are capable of treating all standard radiation therapy indications including breast, prostate, lung and head and neck cancers, in addition to complex and novel treatments such as total marrow irradiation. The Radixact System, the next generation TomoTherapy System, includes our integrated Accuray Precision treatment planning software and new iDMS Data Management System. The Radixact System leverages the TomoTherapy System’s efficient daily low-dose fan beam MVCT image guidance and unique ring gantry architecture, delivering precise radiation treatments for more patients, faster, with simpler, more automated workflows. We believe Radixact Systems and other TomoTherapy Systems offer clinicians and patients significant benefits over other radiation therapy systems in the market. We believe our ability to capture more sales will be influenced by a number of factors including the following:
· Continued adoption of our TomoTherapy Systems, including the adoption of Radixact Systems in markets where it is available;
· Greater awareness among doctors and patients of the unique benefits of radiation therapy using TomoTherapy Systems because of their ring gantry architecture and ability to deliver treatment from 360 degrees around the patient;
· Advances in our technology that improve the quality of treatments and ease of use of TomoTherapy Systems;
· Greater awareness among doctors of the now-established reliability of TomoTherapy Systems; and
· Our ability to expand sales of TomoTherapy Systems in countries throughout the world where we do not currently sell or have not historically sold a significant number of TomoTherapy Systems.
Sale of Our Products
Generating revenue from the sale of our systems is a lengthy process. Selling our systems, from first contact with a potential customer to a signed sales contract that meets our backlog criteria (as discussed below) varies significantly and generally spans between six months and two years. The length of time between receipt of a signed contract and revenue recognition is generally governed by the time required by the customer to build, renovate or prepare the treatment room for installation of the system.
In the United States, we primarily market directly to customers, including hospitals and stand-alone treatment facilities, through our sales organization and we also market to customers through sales agents and group purchasing organizations. Outside the United States, we market to customers directly and through distributors and sales agents. In addition to our offices in the United States, we have sales and service offices in Europe, Asia, and South America.
Backlog
For orders that cover both products and services, only the portion of the order that is recognizable as product revenue is reported as backlog. The portion of the order that is recognized as service revenue (for example, Post-Contract Customer Support (PCS), installation, training and professional services) is not included in reported backlog. Product backlog totaled $470.5 million as of December 31, 2017 compared to $452.8 million as of June 30, 2017.
In order for the product portion of a system sales agreement to be counted as backlog, it must meet the following criteria:
· The contract is properly executed by both the customer and us. A customer purchase order that incorporates the terms of our contract quote will be considered equivalent to a signed and executed contract. The contract has either cleared all its contingencies or contained no contingencies when signed.
· We have received a minimum deposit or a letter of credit; or the sale is to a customer where a deposit is deemed not necessary or customary (i.e. sale to a government entity, a large hospital, group of hospitals or cancer care group that has sufficient credit, customers with trade-in of existing equipment, sales via tender awards, or indirect channel sales that have signed contracts with end-customers);
· The specific end customer site has been identified by the customer in the written contract or written amendment; and
· Less than 2.5 years have passed since the contract met all the criteria above.
Although our backlog includes only contractual agreements with our customers for the purchase of CyberKnife Systems, TomoTherapy Systems, including Radixact Systems and related upgrades, we cannot provide assurance that we will convert backlog into recognized revenue due primarily to factors outside of our control. The amount of backlog recognized into revenue is primarily impacted by three items: cancellations, age-outs and foreign currency fluctuations. Orders could be cancelled for reasons including, without limitation, changes in customers’ needs or financial condition, changes in government or health insurance reimbursement policies, or changes to regulatory requirements. In addition to cancellations, after 2.5 years, if we have not been able to recognize revenue on a contract, we remove the revenue associated with the contract from backlog and the order is considered aged out. Contracts may age-out for many reasons, including but not limited to, inability of the customer to pay, inability of the customer to adapt their facilities to accommodate our products in a timely manner, or inability to timely obtain licenses necessary for customer facilities or operation of our equipment. Our backlog also includes amounts not denominated in U.S. Dollars and therefore fluctuations in the U.S. Dollar as compared to other currencies will impact revenue. Generally, strengthening of the U.S. Dollar will negatively impact revenue. Backlog is stated at historical foreign currency exchange rates, and revenue is released from backlog at current exchange rates, with any difference recorded as a backlog adjustment.
A summary of gross orders, net orders, and order backlog is as follows (in thousands):
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
|
December 31, |
|
December 31, |
| ||||||||
|
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
| ||||
|
Gross orders |
|
$ |
77,908 |
|
$ |
78,454 |
|
$ |
133,554 |
|
$ |
128,789 |
|
|
Net orders |
|
52,649 |
|
54,069 |
|
103,687 |
|
91,256 |
| ||||
|
Order backlog at the end of the period |
|
470,511 |
|
426,158 |
|
470,511 |
|
426,158 |
| ||||
Gross Orders
Gross orders are defined as the sum of new orders recorded during the period adjusted for any revisions to existing orders during the period.
Gross orders decreased by $0.5 million for the three months ended December 31, 2017, as compared to the three months ended December 31, 2016. This was a result of a decrease of $1.5 million in new system order volume compared to the same prior year period, primarily driven by the decrease of CyberKnife System orders, partially offset by an increase in TomoTherapy System orders driven by Radixact Systems, which were introduced in the second half of fiscal 2017. The decrease in new system orders was partially offset by an increase of $0.9 million in upgrade orders and other amendments as compared to the same prior year period.
Gross orders increased by $4.8 million for the six months ended December 31, 2017, as compared to the six months ended December 31, 2016. This was a result of an increase of $6.7 million in new system order volume compared to the same prior year period primarily driven by TomoTherapy and Radixact System orders. Additionally, the increase in TomoTherapy and Radixact System orders was offset by a decrease in CyberKnife System orders year over year in units and dollars. Upgrade orders decreased by $1.9 million in the six months ended December 31, 207 as compared to the same prior year period.
Net Orders
Net orders are defined as gross orders less cancellations, age-outs, foreign exchange and other adjustments.
Net orders decreased by $1.4 million for the three months ended December 31, 2017, as compared to the three months ended December 31, 2016, resulting from a decrease in gross orders of $0.5 million, an increase in net age-outs of $1.1 million and negative foreign currency adjustments of $0.3 million, offset by cancellation adjustments of $0.5 million.
· The net age-outs for the three months ended December 31, 2017 was $20.9 million. There were no age-ins, which represent orders that previously aged-out but have been taken to revenue in the current period. Age-ins offset the gross amount of age-outs in a particular period.
· There were $3.1 million and $3.6 million in cancellations in the three months ended December 31, 2017 and December 31, 2016, respectively. Cancellations are outside of our control and are difficult to forecast; however, we continue to work closely with our customers to minimize the impact of cancellations on our business.
· Other adjustments and foreign currency impacts decreased net orders by $1.2 million for the three months ended December 31, 2017 while currency impacts resulted in a decrease in net orders of $0.9 million for the three months ended December 31, 2016.
Net orders increased by $12.4 million for the six months ended December 31, 2017, as compared to the six months ended December 31, 2016, resulting from an increase in gross orders of $4.8 million, decreases in net age-outs of $5.1 million and cancellations of $3.9 million, offset by negative foreign currency adjustments of $1.4 million.
· The net age-outs of $25.5 million for the six months ended December 31, 2017 include $9.1 million of age-ins, which represent orders that previously aged-out but have been taken to revenue in the current period. Age-ins offset the gross amount of age-outs in a particular period.
· There were $3.1 million in cancellations in the six months ended December 31, 2017 and $7.0 million in cancellations in the six months ended December 31, 2016. Cancellations are outside of our control and are difficult to forecast, however, we continue to work closely with our customers to minimize the impact of cancellations on our business.
· Other adjustments and foreign currency impacts decreased net orders by $1.3 million for the six months ended December 31, 2017 while currency impacts resulted in a decrease in net orders of $0.1 million for the six months ended December 31, 2016.
Results of Operations — Three and Six months ended December 31, 2017 and 2016
|
|
|
Three Months Ended December 31, |
|
Six Months Ended December 31, |
| ||||||||||||||||
|
|
|
2017 |
|
2016 |
|
Change |
|
2017 |
|
2016 |
|
Change |
| ||||||||
|
(Dollars in thousands) |
|
Amount |
|
Amount |
|
$ |
|
% |
|
Amount |
|
Amount |
|
$ |
|
% |
| ||||
|
Products |
|
$ |
47,106 |
|
$ |
35,398 |
|
11,708 |
|
33 |
|
$ |
86,022 |
|
$ |
70,997 |
|
15,025 |
|
21 |
|
|
Services |
|
53,223 |
|
52,104 |
|
1,119 |
|
2 |
|
105,257 |
|
103,011 |
|
2,246 |
|
2 |
| ||||
|
Net revenue |
|
$ |
100,329 |
|
$ |
87,502 |
|
12,827 |
|
15 |
|
$ |
191,279 |
|
$ |
174,008 |
|
17,271 |
|
10 |
|
|
Gross profit |
|
$ |
39,355 |
|
$ |
31,387 |
|
7,968 |
|
25 |
|
$ |
77,461 |
|
$ |
62,731 |
|
14,730 |
|
23 |
|
|
Products gross profit |
|
20,249 |
|
12,429 |
|
7,820 |
|
63 |
|
37,063 |
|
24,676 |
|
12,387 |
|
50 |
| ||||
|
Services gross profit |
|
19,106 |
|
18,958 |
|
148 |
|
1 |
|
40,398 |
|
38,055 |
|
2,343 |
|
6 |
| ||||
|
Research and development expenses |
|
14,664 |
|
11,944 |
|
2,720 |
|
23 |
|
28,757 |
|
24,173 |
|
4,584 |
|
19 |
| ||||
|
Selling and marketing expenses |
|
13,872 |
|
13,904 |
|
(32 |
) |
— |
|
28,629 |
|
28,222 |
|
407 |
|
1 |
| ||||
|
General and administrative expenses |
|
11,836 |
|
10,362 |
|
1,474 |
|
14 |
|
23,144 |
|
21,706 |
|
1,438 |
|
7 |
| ||||
|
Other expense, net |
|
3,738 |
|
4,120 |
|
(382 |
) |
(9 |
) |
10,309 |
|
8,125 |
|
2,184 |
|
27 |
| ||||
|
Provision for (benefit from) income taxes |
|
(36 |
) |
426 |
|
(462 |
) |
108 |
|
723 |
|
(200 |
) |
923 |
|
462 |
| ||||
|
Net loss |
|
$ |
(4,719 |
) |
$ |
(9,369 |
) |
4,650 |
|
50 |
|
$ |
(14,101 |
) |
$ |
(19,295 |
) |
5,194 |
|
27 |
|
Net Revenue
|
|
|
Three Months Ended December 31, |
|
Six Months Ended December 31, |
| ||||||||||||||||
|
|
|
2017 |
|
2016 |
|
Change |
|
2017 |
|
2016 |
|
Change |
| ||||||||
|
(Dollars in thousands) |
|
Amount |
|
Amount |
|
$ |
|
% |
|
Amount |
|
Amount |
|
$ |
|
% |
| ||||
|
Products |
|
$ |
47,106 |
|
$ |
35,398 |
|
11,708 |
|
33 |
|
$ |
86,022 |
|
$ |
70,997 |
|
15,025 |
|
21 |
|
|
Services |
|
53,223 |
|
52,104 |
|
1,119 |
|
2 |
|
105,257 |
|
103,011 |
|
2,246 |
|
2 |
| ||||
|
Net revenue |
|
$ |
100,329 |
|
$ |
87,502 |
|
12,827 |
|
15 |
|
$ |
191,279 |
|
$ |
174,008 |
|
17,271 |
|
10 |
|
Product Net Revenue.
Product net revenue increased by $11.7 million for the three months ended December 31, 2017, as compared to the three months ended December 31, 2016, primarily due to an increase in sales of Radixact Systems, which was commercially launched in prior fiscal year, as well as improved backlog conversion of orders to revenue from the Europe and Asia Pacific regions. In addition to the increase in system revenue of $9.3 million, there was an increase of $2.4 million in upgrade and other revenue as compared to the prior year period.
Product net revenue increased by $15.0 million for the six months ended December 31, 2017, as compared to the six months ended December 31, 2016, primarily due to an increase in sales of Radixact Systems, which was commercially launched in prior fiscal year, as well as backlog conversion of orders to revenue from the Europe, Asia Pacific, and Japan regions. In addition to the increase in system revenue of $14.1 million, there was an increase of $0.9 million in upgrade and other revenue as compared to the prior year period.
Services Net Revenue.
Services net revenue increased by $1.1 million for the three months ended December 31, 2017, as compared to the three months ended December 31, 2016. An increase of $2.2 million was attributable to a net increase in our installed base and installation revenue, partially offset by a decrease of $1.1 million in spare parts and training revenue.
Services net revenue increased by $2.2 million for the six months ended December 31, 2017, as compared to the three months ended December 31, 2016. An increase of $3.5 million was attributable to a net increase in our installed base, partially offset by a decrease of $1.3 million in installation, spare parts and training revenue.
Percentage of net revenue by geographic region, based on the shipping location of our customers, is as follows (in thousands, except percentages):
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
|
December 31, |
|
December 31, |
| ||||||||
|
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
| ||||
|
Net revenue |
|
$ |
100,329 |
|
$ |
87,502 |
|
$ |
191,279 |
|
$ |
174,008 |
|
|
Americas |
|
38 |
% |
45 |
% |
39 |
% |
46 |
% | ||||
|
Europe, Middle East, India and Africa |
|
32 |
% |
29 |
% |
35 |
% |
27 |
% | ||||
|
Asia Pacific |
|
30 |
% |
26 |
% |
26 |
% |
27 |
% | ||||
Revenue derived from sales outside of the Americas region as a percentage of our total net revenue increased in both three and six-month periods ended December 31, 2017 over the same periods in the prior year primarily due to improved backlog conversion of orders to revenue in those regions.
Gross Profit
|
|
|
Three Months Ended December 31, |
|
Six Months Ended December 31, |
| ||||||||||||||||
|
|
|
2017 |
|
2016 |
|
Change |
|
2017 |
|
2016 |
|
Change |
| ||||||||
|
(Dollars in thousands) |
|
Amount |
|
Amount |
|
$ |
|
% |
|
Amount |
|
Amount |
|
$ |
|
% |
| ||||
|
Product gross profit |
|
$ |
20,249 |
|
$ |
12,429 |
|
7,820 |
|
63 |
|
$ |
37,063 |
|
$ |
24,676 |
|
12,387 |
|
50 |
|
|
Services gross profit |
|
19,106 |
|
18,958 |
|
148 |
|
1 |
|
40,398 |
|
38,055 |
|
2,343 |
|
6 |
| ||||
|
Gross profit |
|
$ |
39,355 |
|
$ |
31,387 |
|
7,968 |
|
25 |
|
$ |
77,461 |
|
$ |
62,731 |
|
14,730 |
|
23 |
|
Overall gross profit for the three months ended December 31, 2017 increased $8.0 million, or 25%, as compared to the three months ended December 31, 2016, primarily due to the increase in product gross margin, which was favorably impacted by product volume and unit mix in the second quarter of fiscal 2018 as compared to the same period in the prior fiscal year. Further, in prior fiscal periods, we recorded a quarterly $2.0 million intangible amortization charge related to the acquisition of TomoTherapy Incorporated, which was fully amortized in the fourth quarter of our fiscal year 2017.
Overall gross profit for the six months ended December 31, 2017 increased $14.7 million, or 23%, as compared to the six months ended December 31, 2016. Product gross margin increased 50%, or $12.4 million, primarily due to favorable volume and unit mix in the first half of fiscal 2018 as compared to the same period in the prior fiscal year. Further, in the first half of fiscal 2017, we recorded $4.0 million of intangible amortization related to the acquisition of TomoTherapy Incorporated, which was fully amortized in the fourth quarter of our fiscal year 2017. The increase was partially offset by $0.8 million in higher inventory reserves for the six months ended December 31, 2017.
Service gross margin was relatively flat for the three months ended December 31, 2017 and December 31, 2016 and service gross margin increased 6% for the six months ended December 31, 2017 and December 31, 2016, respectively due primarily to the continued installed base expansion.
Research and Development
|
|
|
Three Months Ended December 31, |
|
Six Months Ended December 31, |
| ||||||||||||||
|
|
|
2017 |
|
2016 |
|
Change |
|
2017 |
|
2016 |
|
Change |
| ||||||
|
(Dollars in thousands) |
|
Amount |
|
Amount |
|
$ |
|
% |
|
Amount |
|
Amount |
|
$ |
|
% |
| ||
|
Research and development expenses |
|
$ |
14,664 |
|
$ |
11,944 |
|
2,720 |
|
23 |
|
28,757 |
|
24,173 |
|
4,584 |
|
19 |
|
Research and development expenses increased by $2.7 million in the three months ended December 31, 2017, as compared to the same period in the prior year. The increase was primarily due to $1.9 million of higher compensation expenses for additional headcount and $0.7 million in higher consulting fees, both of which were for projects related to our product development as well as an increase of $0.1 million in IT and facilities expenses to support increased headcount.
Research and development expenses increased by $4.6 million in the six months ended December 31, 2017, as compared to the same period in the prior year. The increase was primarily due to $3.3 million of higher compensation expenses for additional headcount and $1.2 million in higher consulting fees, both of which were for projects related to our product development.
Selling and Marketing
|
|
|
Three Months Ended December 31, |
|
Six Months Ended December 31, |
| ||||||||||||||
|
|
|
2017 |
|
2016 |
|
Change |
|
2017 |
|
2016 |
|
Change |
| ||||||
|
(Dollars in thousands) |
|
Amount |
|
Amount |
|
$ |
|
% |
|
Amount |
|
Amount |
|
$ |
|
% |
| ||
|
Selling and marketing expenses |
|
$ |
13,872 |
|
$ |
13,904 |
|
(32 |
) |
— |
|
28,629 |
|
28,222 |
|
407 |
|
1 |
|
Selling and marketing expenses remained flat for the three months ended December 31, 2017, as compared to the same period in the prior year.
Selling and marketing expenses increased by $0.4 million in the six months ended December 31, 2017, as compared to the same period in the prior year. The increase was primarily due to $0.1 million in higher compensation expenses related to commissions, $0.1 million in higher tradeshow and advertising costs, and $0.2 million in higher IT and facilities expenses.
General and Administrative
|
|
|
Three Months Ended December 31, |
|
Six Months Ended December 31, |
| ||||||||||||||
|
|
|
2017 |
|
2016 |
|
Change |
|
2017 |
|
2016 |
|
Change |
| ||||||
|
(Dollars in thousands) |
|
Amount |
|
Amount |
|
$ |
|
% |
|
Amount |
|
Amount |
|
$ |
|
% |
| ||
|
General and administrative expenses |
|
$ |
11,836 |
|
$ |
10,362 |
|
1,474 |
|
14 |
|
23,144 |
|
21,706 |
|
1,438 |
|
7 |
|
General and administrative expenses increased by $1.5 million in the three months ended December 31, 2017, as compared to the same period in the prior year. The increase was primarily due to $0.9 million in higher consulting expenses related to strategic business development, travel, and recruiting fees, $0.5 million in higher stock based compensation expense and $0.1 million in higher IT and facilities expenses.
General and administrative expenses increased by $1.4 million in the six months ended December 31, 2017 as compared to the same period in the prior year. The increase was primarily due to $1.2 million in higher consulting expenses related to strategic business development, travel and recruiting fees and $0.2 million in higher stock based compensation expenses.
Other Expense, net
|
|
|
Three Months Ended December 31, |
|
Six Months Ended December 31, |
| ||||||||||||||
|
|
|
2017 |
<|||||||||||||||||